Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2527522 | Clinical Therapeutics | 2012 | 13 Pages |
Abstract
Because of data available, health outcomes of the first-line rituximab induction were excluded, the second-line patients on COP were assumed to incur the cost of COP, and the efficacy and adverse events of CHOP and the efficacy and adverse events of bendamustine were estimated indirectly according to a comparison of rituximab+bendamustine and RCHOP, and treatment benefits were truncated.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Erkki J. MSc, Janne A. PhD, Ville MSc, Kim MSc, Tapio MD, PhD,